{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:43:06Z","timestamp":1789954986669,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10689-017-0049-z","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T06:14:57Z","timestamp":1509084897000},"page":"451-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness evaluation of pre-counseling telephone interviews before face-to-face genetic counseling in cancer genetics"],"prefix":"10.1007","volume":"17","author":[{"given":"Ga\u00eblle","family":"Collet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Cassinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Neviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Gasnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afane","family":"Brahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lecoquierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Thery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Tennevet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lacaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Berthet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Frebourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"49_CR1","unstructured":"Cancer French Institute (2017) Cancer genetics national plan. \n                        http:\/\/www.e-cancer.fr\/Professionnels-de-sante\/L-organisation-de-l-offre-de-soins\/Oncogenetique\/Le-dispositif-national-d-oncogenetique\n                        \n                    . Accessed 26 Jan 2017"},{"key":"49_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s1019801708875","author":"D M\u00fcller","year":"2017","unstructured":"M\u00fcller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L et al (2017) Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. Eur J Health Econ. doi:\n                        10.1007\/s1019801708875","journal-title":"Eur J Health Econ"},{"issue":"4","key":"49_CR3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/M13-1684","volume":"160","author":"HD Nelson","year":"2014","unstructured":"Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 160(4):255\u2013266","journal-title":"Ann Intern Med"},{"issue":"5","key":"49_CR4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/j.seminoncol.2016.10.001","volume":"43","author":"EF Cobain","year":"2016","unstructured":"Cobain EF, Milliron KJ, Merajver SD (2016) Updates on breast cancer genetics: clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. Semin Oncol 43(5):528\u2013535","journal-title":"Semin Oncol"},{"issue":"2","key":"49_CR5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-016-3805-0","volume":"157","author":"D Madorsky-Feldman","year":"2016","unstructured":"Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R et al (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157(2):319\u2013327","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"49_CR6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-014-2890-1","volume":"144","author":"A Valachis","year":"2014","unstructured":"Valachis A, Nearchou AD, Lind P (2014) Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat 144(3):443\u2013455","journal-title":"Breast Cancer Res Treat"},{"key":"49_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/jygyno201705037","author":"EM Bednar","year":"2017","unstructured":"Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH (2017) A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. doi:\n                        10.1016\/jygyno201705037","journal-title":"Gynecol Oncol"},{"issue":"4","key":"49_CR8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1758834016687254","volume":"9","author":"T Evans","year":"2017","unstructured":"Evans T, Matulonis U (2017) PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol 9(4):253\u2013267","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"49_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10897-016-9983-4","volume":"26","author":"AL Shugar","year":"2017","unstructured":"Shugar AL, Quercia N, Trevors C, Rabideau MM, Ahmed S (2017) Risk for patient harm in Canadian genetic counseling practice: it\u2019s time to consider regulation. J Genet Couns 26(1):93\u2013104","journal-title":"J Genet Couns"},{"key":"49_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s1089701700720","author":"G Cicero","year":"2017","unstructured":"Cicero G, De Luca R, Dorangricchia P, Lo Coco G, Guarnaccia C, Fanale D et al (2017) Risk perception and psychological distress in genetic counselling for hereditary breast and\/or ovarian cancer. J Genet Couns. doi:\n                        10.1007\/s1089701700720","journal-title":"J Genet Couns"},{"key":"49_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s108970170090y","author":"HS Lumish","year":"2017","unstructured":"Lumish HS, Steinfeld H, Koval C, Russo D, Levinson E, Wynn J et al (2017) Impact of panel gene testing for hereditary breast and ovarian cancer on patients. J Genet Couns. doi:\n                        10.1007\/s108970170090y","journal-title":"J Genet Couns"},{"issue":"8","key":"49_CR12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","volume":"91","author":"AC Antoniou","year":"2004","unstructured":"Antoniou AC, Pharoah PP, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580\u20131590","journal-title":"Br J Cancer"},{"issue":"7","key":"49_CR13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","volume":"32","author":"MD Schwartz","year":"2014","unstructured":"Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT et al (2014) Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 32(7):618\u2013626","journal-title":"J Clin Oncol"},{"issue":"2","key":"49_CR14","first-page":"143","volume":"13","author":"AS Sie","year":"2014","unstructured":"Sie AS, van Zelst-Stams WA, Spruijt L, Mensenkamp AR, Ligtenberg MJ, Brunner HG et al (2014) More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer 13(2):143\u2013151","journal-title":"Fam Cancer"},{"issue":"24","key":"49_CR15","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2015.65.9557","volume":"34","author":"AY Kinney","year":"2016","unstructured":"Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH et al (2016) Randomized noninferiority trial of telephone delivery of BRCA1\/2 genetic counseling compared with in-person counseling: 1-year follow-up. J Clin Oncol 34(24):2914\u20132924","journal-title":"J Clin Oncol"},{"issue":"6","key":"49_CR16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ejhg.2015.196","volume":"24","author":"H H\u00f8berg-Vetti","year":"2016","unstructured":"H\u00f8berg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H et al (2016) BRCA1\/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet 24(6):881\u2013888","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"49_CR17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s10897-015-9899-4","volume":"25","author":"AS Sie","year":"2016","unstructured":"Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG et al (2016) High satisfaction and low distress in breast cancer patients one year after BRCA-mutation testing without prior face-to-face genetic counseling. J Genet Couns 25(3):504\u2013514","journal-title":"J Genet Couns"},{"issue":"1","key":"49_CR18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10897-016-9996-z","volume":"26","author":"MT Augestad","year":"2017","unstructured":"Augestad MT, H\u00f8berg-Vetti H, Bjorvatn C, Sekse RJ (2017) Identifying needs: a qualitative study of women\u2019s experiences regarding rapid genetic testing for hereditary breast and ovarian cancer in the DNA BONus Study. J Genet Couns 26(1):182\u2013189","journal-title":"J Genet Couns"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-017-0049-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-017-0049-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-017-0049-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T03:31:53Z","timestamp":1528860713000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-017-0049-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1007\/s10689-017-0049-z","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]}}}